PMID- 35259044
OWN - NLM
STAT- MEDLINE
DCOM- 20220408
LR  - 20220606
IS  - 2165-5987 (Electronic)
IS  - 2165-5979 (Print)
IS  - 2165-5979 (Linking)
VI  - 13
IP  - 3
DP  - 2022 Mar
TI  - Circular RNA hsa_circ_0011324 is involved in endometrial cancer progression and 
      the evolution of its mechanism.
PG  - 7485-7499
LID - 10.1080/21655979.2022.2049026 [doi]
AB  - Endometrial cancer (EC) is one of the most common gynecological tumors with an 
      increasing incidence. CircRNA plays an essential regulatory role in EC. Our 
      objective was to investigate the potential mechanism of circRNAs derived SPOC 
      Domain Containing 1 (SPOCD1) in EC progression. Seven circRNAs from SPOCD1 were 
      analyzed by circBase and their expression was verified by quantitative real-time 
      polymerase chain reaction. Only the expression of hsa_circ_0011324 was 
      significantly increased in cancer tissues. The cell lines Ishikawa and RL95-2 
      which interfered with or overexpressed hsa_circ_0011324 were constructed and cell 
      functions were tested. Results revealed hsa_circ_0011324 overexpression promoted 
      cell proliferation, migration, and invasion; while silence of hsa_circ_0011324 
      had opposite effect on cell functions. RNA22 website and Targetscan website were 
      applied to analyze downstream genes regulated by hsa_circ_0011324. Then, the 
      expression of downstream genes was detected in EC tissues. Results indicated 
      hsa-miR-497/16-5p expression were down-regulated, and mechanistic target of 
      rapamycin kinase (mTOR) was up-regulated in EC. Furthermore, hsa_circ_0011324 
      regulated mTOR expression and cell functions by affecting hsa-miR-497/16-5p. And 
      the potential mechanism was hsa_circ_0011324 competes with mTOR to directly bind 
      to hsa-miR-497/16-5p. In conclusion, hsa_circ_0011324 could sponge 
      hsa-miR-497/16-5p targeted mTOR to participate in EC progress. Our study may 
      provide a new therapeutic target for EC.
FAU - Liu, Dajiang
AU  - Liu D
AD  - Department of Obstetrics and Gynecology, The first Hospital of Lanzhou 
      University, Gansu, Lanzhou, China.
FAU - Bi, Xuehan
AU  - Bi X
AD  - Department of Obstetrics and Gynecology, The first Hospital of Lanzhou 
      University, Gansu, Lanzhou, China.
FAU - Yang, Yongxiu
AU  - Yang Y
AD  - Department of Obstetrics and Gynecology, The first Hospital of Lanzhou 
      University, Gansu, Lanzhou, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Bioengineered
JT  - Bioengineered
JID - 101581063
RN  - 0 (MIRN497 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (RNA, Circular)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Cell Proliferation/genetics
MH  - *Endometrial Neoplasms/genetics/pathology
MH  - Female
MH  - Humans
MH  - *MicroRNAs/genetics/metabolism
MH  - RNA, Circular/genetics
MH  - TOR Serine-Threonine Kinases/genetics
PMC - PMC8973664
OTO - NOTNLM
OT  - Hsa_circ_0011324
OT  - endometrial cancer
OT  - hsa-miR-16-5p
OT  - hsa-miR-497-5p
OT  - mechanistic target of rapamycin kinase
COIS- No potential conflict of interest was reported by the author(s).
EDAT- 2022/03/09 06:00
MHDA- 2022/04/09 06:00
PMCR- 2022/03/08
CRDT- 2022/03/08 17:11
PHST- 2022/03/08 17:11 [entrez]
PHST- 2022/03/09 06:00 [pubmed]
PHST- 2022/04/09 06:00 [medline]
PHST- 2022/03/08 00:00 [pmc-release]
AID - 2049026 [pii]
AID - 10.1080/21655979.2022.2049026 [doi]
PST - ppublish
SO  - Bioengineered. 2022 Mar;13(3):7485-7499. doi: 10.1080/21655979.2022.2049026.